$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010351 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$49.00K	$56.00K	$141.0K
YoY Change	48.48%	12.0%	4.44%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Gross Profit	$49.00K	$56.00K	$141.0K
YoY Change	-211.36%	-144.44%	-119.72%
Gross Profit Margin	100.0%	100.0%	100.0%
Selling, General & Admin	$2.292M	$3.505M	$13.07M
YoY Change	10.62%	33.93%	50.76%
% of Gross Profit	4677.55%	6258.93%	9272.34%
Research & Development	$2.052M	$2.107M	$6.990M
YoY Change	98.07%	-27.92%	-8.89%
% of Gross Profit	4187.76%	3762.5%	4957.45%
Depreciation & Amortization	$11.00K	$170.0K	$38.00K
YoY Change	-62.07%	-12.37%	-95.1%
% of Gross Profit	22.45%	303.57%	26.95%
Operating Expenses	$2.052M	$5.612M	$6.990M
YoY Change	-33.98%	1.3%	-57.23%
Operating Profit	-$4.295M	-$5.556M	-$19.92M
YoY Change	36.26%	-1.94%	16.79%
Interest Expense	$402.0K	$423.0K
YoY Change		-240.53%
% of Operating Profit
Other Income/Expense, Net	$199.0K	$0.00	$629.0K
YoY Change	541.94%	-100.0%	333.79%
Pretax Income	-$3.661M	-$4.389M	-$19.45M
YoY Change	-4.16%	-24.92%	1.66%
Income Tax
% Of Pretax Income
Net Earnings	-$3.661M	-$4.389M	-$19.45M
YoY Change	-4.16%	-24.92%	1.66%
Net Earnings / Revenue	-7471.43%	-7837.5%	-13790.78%
Basic Earnings Per Share	-$0.08		-$0.40
Diluted Earnings Per Share	-$0.08	-$0.09	-$0.40
COMMON SHARES
Basic Shares Outstanding	48.41M shares	48.08M shares
Diluted Shares Outstanding	48.40M shares		48.05M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.85M	$34.19M	$34.19M
YoY Change	-30.74%	-29.17%	-29.17%
Cash & Equivalents	$23.40M	$27.05M	$27.05M
Short-Term Investments	$7.454M	$7.137M	$7.137M
Other Short-Term Assets	$548.0K	$455.0K	$455.0K
YoY Change	-86.94%	49.67%	49.67%
Inventory
Prepaid Expenses
Receivables	$1.763M	$1.676M	$1.676M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.16M	$36.32M	$36.32M
YoY Change	-34.18%	-27.67%	-27.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$155.0K	$195.0K	$1.024M
YoY Change	-44.84%	-95.18%	-75.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.457M	$1.202M	$1.202M
YoY Change	-3.25%	-8.66%	-8.66%
Total Long-Term Assets	$4.302M	$4.167M	$4.167M
YoY Change	13.96%	-44.34%	-44.34%
TOTAL ASSETS
Total Short-Term Assets	$33.16M	$36.32M	$36.32M
Total Long-Term Assets	$4.302M	$4.167M	$4.167M
Total Assets	$37.46M	$40.49M	$40.49M
YoY Change	-30.82%	-29.83%	-29.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$963.0K	$377.0K	$377.0K
YoY Change	154.76%	90.4%	90.4%
Accrued Expenses	$696.0K	$806.0K	$984.0K
YoY Change	79.38%	84.02%	107.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.837M	$1.361M	$1.361M
YoY Change	139.82%	102.23%	102.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$636.0K	$659.0K	$659.0K
YoY Change	622.73%	348.3%	348.3%
Total Long-Term Liabilities	$636.0K	$659.0K	$659.0K
YoY Change	622.73%		348.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.837M	$1.361M	$1.361M
Total Long-Term Liabilities	$636.0K	$659.0K	$659.0K
Total Liabilities	$2.473M	$2.020M	$2.020M
YoY Change	189.58%	200.15%	146.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$384.2M	-$380.5M
YoY Change		5.38%
Common Stock	$48.00K	$48.00K
YoY Change		-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.99M	$38.47M	$38.47M
YoY Change
Total Liabilities & Shareholders Equity	$37.46M	$40.49M	$40.49M
YoY Change	-30.82%	-29.83%	-29.83%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.661M	-$4.389M	-$19.45M
YoY Change	-4.16%	-24.92%	1.66%
Depreciation, Depletion And Amortization	$11.00K	$170.0K	$38.00K
YoY Change	-62.07%	-12.37%	-95.1%
Cash From Operating Activities	-$3.680M	-$6.069M	-$16.11M
YoY Change	33.43%	5.64%	15.35%
INVESTING ACTIVITIES
Capital Expenditures		$175.0K	$86.00K
YoY Change		-212.9%	-113.59%
Acquisitions
YoY Change
Other Investing Activities	-$78.00K	$3.538M	$11.26M
YoY Change	-75.08%	581.7%	562850.0%
Cash From Investing Activities	-$78.00K	$3.363M	$10.99M
YoY Change	-77.46%	823.9%	-1841.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$100.0K	0.000	$80.00K
YoY Change		-100.0%	-99.02%
NET CHANGE
Cash From Operating Activities	-$3.680M	-6.069M	-$16.11M
Cash From Investing Activities	-$78.00K	3.363M	$10.99M
Cash From Financing Activities	$100.0K	0.000	$80.00K
Net Change In Cash	-$3.658M	-2.706M	-$5.040M
YoY Change		-48.52%	-21.35%
FREE CASH FLOW
Cash From Operating Activities	-$3.680M	-$6.069M	-$16.11M
Capital Expenditures		$175.0K	$86.00K
Free Cash Flow		-$6.244M	-$16.19M
YoY Change		11.7%	21.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	AIM	Redeemable Warrants RedeemableWarrants		usd
CY2022	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost		usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2022Q2	dei	Entity Public Float EntityPublicFloat	36254483	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48407326	shares
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	AIM	Stock Issued During Value Of Warrant Modification StockIssuedDuringValueOfWarrantModification		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	AIM	Extinguishment Of Financing Obligation And Note Payables ExtinguishmentOfFinancingObligationAndNotePayables		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2022	AIM	Payment Of Financing Obligation PaymentOfFinancingObligation		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q4	us-gaap	Land And Land Improvements LandAndLandImprovements		usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2021Q4	AIM	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	AIM	Redeemable Warrants RedeemableWarrants		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-27072
CY2022	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
CY2022	dei	City Area Code CityAreaCode	(352)
CY2022	dei	Local Phone Number LocalPhoneNumber	448-7797
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	AIM
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Miami, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27053000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32093000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1676000	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1641000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	455000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	304000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36321000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	50213000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4047000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1941000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1974000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1202000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1316000	usd
CY2022Q4	us-gaap	Assets Assets	40488000	usd
CY2021Q4	us-gaap	Assets Assets	57699000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	377000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	198000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	438000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	37000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1361000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	673000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	659000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112000	usd
CY2021Q4	AIM	Redeemable Warrants RedeemableWarrants	35000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	696000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	715000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994672	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418270000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	417217000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380546000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-361101000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40488000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57699000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	141000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135000	usd
CY2021	us-gaap	Manufacturing Costs ManufacturingCosts	850000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6990000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7672000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13074000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8672000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1779000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	20064000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	18973000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-19923000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18838000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1679000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-201000	usd
CY2021	us-gaap	Interest Expense InterestExpense	67000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	629000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2701000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	216000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-145000	usd
CY2022	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-1490000	usd
CY2021	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-2319000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19445000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19127000	usd
CY2021	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost	376000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-329000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19445000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19080000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48047288	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47339975	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	61294000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13042000	usd
CY2021	AIM	Shares Issued To Pay Accounts Payable SharesIssuedToPayAccountsPayable	55000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19080000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	954000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19445000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19445000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19127000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2021	us-gaap	Depreciation Depreciation	659000	usd
CY2022	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment	-35000	usd
CY2021	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment	-145000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	216000	usd
CY2021	AIM	Extinguishment Of Financing Obligation And Note Payables ExtinguishmentOfFinancingObligationAndNotePayables	2701000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	218000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000	usd
CY2022	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	-680000	usd
CY2021	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	30000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1779000	usd
CY2022	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	-197000	usd
CY2021	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	2319000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	954000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1568000	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1679000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-47000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	47000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	35000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	551000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1631000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	688000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-30000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	83000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	179000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-185000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	368000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16108000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13965000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10083000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22292000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2724000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22535000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3900000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	245000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	185000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	592000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10988000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-631000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	122000	usd
CY2021	AIM	Payment Of Financing Obligation PaymentOfFinancingObligation	4732000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	80000	usd
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13042000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8188000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5040000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38501000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	55000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-928000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-88000	usd
CY2022	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	19000	usd
CY2021	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	17000	usd
CY2022	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	680000	usd
CY2021	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	18000	usd
CY2022Q4	us-gaap	Area Of Land AreaOfLand	30000	sqft
CY2021Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	3900000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2233000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2353000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2233000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6253000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2038000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2206000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4047000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2021	us-gaap	Depreciation Depreciation	659000	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1800000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zrD23gcQlJIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <span id="xdx_864_zEyJmbRiUNzd">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, building valuation, fair value of warrants, and contingency accruals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2966538	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2150163	shares
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	7137000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1679000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-751000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-928000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	16175000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-88000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-88000	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1498000	usd
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	592000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1974000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	375000	usd
CY2022	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	190	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	218000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	177000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	166000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	161000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	159000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	149000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1129000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	492000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	169000	usd
CY2022Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	110000	usd
CY2021Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	61000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	207000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	438000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	8.80
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994672	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	AIM	Weighted Average Grant Date Fair Value For Options And Equity Warrants Issued WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued	0.51 per option for 850,000 options
CY2021	AIM	Weighted Average Grant Date Fair Value For Options And Equity Warrants Issued WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued	1.61 per option for 613,512 options
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	217000	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	779000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	114	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	568	shares
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.06	pure
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	122000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	139000	usd
CY2022	AIM	Employee Benefits And Share Based Compensation Expenses EmployeeBenefitsAndShareBasedCompensationExpenses	66000	usd
CY2021	AIM	Employee Benefits And Share Based Compensation Expenses EmployeeBenefitsAndShareBasedCompensationExpenses	105000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4M
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M19D
CY2022	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2021	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	271000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	243000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	216000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	200000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	133000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	226000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	149000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	190000	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	67000	usd
CY2022	us-gaap	Short Term Lease Payments ShortTermLeasePayments	56000	usd
CY2021	us-gaap	Short Term Lease Payments ShortTermLeasePayments	12000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19674000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15988000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7647000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7077000	usd
CY2022Q4	AIM	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	2342000	usd
CY2021Q4	AIM	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	1107000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	744000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	82000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	77000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	54000	usd
CY2022Q4	AIM	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	2000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	63000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	708000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30549000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29431000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23711000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1118000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1305000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-19498000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4095000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1640000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.084	pure
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1590000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.082	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1606000	usd
CY2022	AIM	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-0.082	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5719000	usd
CY2022	AIM	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Valuation Allowance EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance	-0.294	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	AIM	Percentage Of Probability PercentageOfProbability	0.050	pure
CY2022	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2021Q4	AIM	Redeemable Warrants RedeemableWarrants	35000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	3900000	usd
CY2021	us-gaap	Gain Loss On Fair Value Hedge Ineffectiveness Net GainLossOnFairValueHedgeIneffectivenessNet	1800000	usd
CY2022	us-gaap	Property Plant And Equipment Collections Not Capitalized Deaccessed Fair Value PropertyPlantAndEquipmentCollectionsNotCapitalizedDeaccessedFairValue	3900000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1800000	usd
CY2018Q1	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	4080000	usd
CY2018Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments will increase 2.5% per year for the next three years through March 31, 2023, and the lease payments will increase 3% for the remaining five years through March 31, 2028
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	73314	shares
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.05
CY2018Q1	AIM	Warrant Closing Price Percentages WarrantClosingPricePercentages	1.25	pure
CY2021Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	4732637	usd

Files In Submission

Name	View Source	Status
aim-20221231_def.xml	Edgar Link	unprocessable
aim-20221231_cal.xml	Edgar Link	unprocessable
aim-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-010351-index-headers.html	Edgar Link	pending
0001493152-23-010351-index.html	Edgar Link	pending
0001493152-23-010351.txt	Edgar Link	pending
0001493152-23-010351-xbrl.zip	Edgar Link	pending
aim-20221231.xsd	Edgar Link	pending
ex10-93.htm	Edgar Link	pending
ex10-94.htm	Edgar Link	pending
ex10-95.htm	Edgar Link	pending
ex10-96.htm	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex3-7.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-25.htm	Edgar Link	pending
aim-20221231_pre.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2023 Q1 Form 10-K Financial Statement

#000149315223010351 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2023 Q1 Form 10-K Financial Statement

#000149315223010351 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim